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A new class of N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide inhibitors of influenza virus hemagglutinin
(HA)-mediated membrane fusion that has a narrow and defined structure-activity relationship was identified.
In Madin-Darby canine kidney (MDCK) cells infected with different strains of human influenza virus A/H3N2,
the lead compound, 4c, displayed a 50% effective concentration of 3 to 23 M and an antiviral selectivity index
of 10. No activity was observed for A/H1N1, A/H5N1, A/H7N2, and B viruses. The activity of 4c was reduced
considerably when added 30 min or later postinfection, indicating that 4c inhibits an early step in virus
replication. 4c and its congeners inhibited influenza A/H3N2 virus-induced erythrocyte hemolysis at low pH.
4c-resistant virus mutants, selected in MDCK cells, contained either a single D112N change in the HA2 subunit
of the viral HA or a combination of three substitutions, i.e., R220S (in HA1) and E57K (in HA2) and an A-T
substitution at position 43 or 96 of HA2. The mutants showed efficiency for receptor binding and replication
similar to that of wild-type virus yet displayed an increased pH of erythrocyte hemolysis. In polykaryon assays
with cells expressing single-mutant HA proteins, the E57K, A96T, and D112N mutations resulted in 4c
resistance, and the HA proteins containing R220S, A96T, and D112N mutations displayed an increased fusion
pH. Molecular modeling identified a binding cavity for 4c involving arginine-54 and glutamic acid-57 in the
HA2 subunit. Our studies with the new fusion inhibitor 4c confirm the importance of this HA region in the
development of influenza virus fusion inhibitors.
Currently available drugs for the prevention and treatment
of seasonal influenza virus infections are the M2 ion channel
blockers (amantadine and rimantadine) and the neuramini-
dase (NA) inhibitors (oseltamivir and zanamivir) (9). The clin-
ical usefulness of amantadine and rimantadine is limited due to
the increasing incidence of adamantane-resistant viruses in the
population (3, 11). Moreover, the M2 ion channel blockers
inhibit only influenza A virus replication and are associated
with neurological side effects. NA inhibitors are favored clin-
ically, since they are effective against all NA subtypes, are well
tolerated, and have a higher barrier for resistance (27). How-
ever, drug-resistant isolates have been detected in A/H3N2-
and A/H5N1-infected patients receiving oseltamivir treatment
(10, 16). Even more reason for concern is the recent and
worldwide isolation of oseltamivir-resistant A/H1N1 mutants,
even among untreated patients (17, 46). Oseltamivir and, to a
lesser extent, zanamivir have been stockpiled as part of pan-
demic preparedness plans and form the cornerstone of the
response to the recent outbreak of the swine flu A/H1N1 virus
(39, 40). However, it is unclear whether these antivirals will be
sufficient to deal with larger influenza epidemics, so there is an
urgent need to develop antivirals that act on a novel influenza
virus target.
An attractive antiviral strategy is to block influenza virus
entry into the host cell, a process in which the viral hemagglu-
tinin (HA) plays a key role (42). HA is a trimeric envelope
glycoprotein that contains two disulfide-linked polypeptide
chains, HA1 and HA2. After attachment of the receptor bind-
ing domain in the HA1 subunit to sialic acid-containing cell
surface glycans, the virion is internalized by endocytosis. The
acidic pH of the endosome leads to an extensive and irrevers-
ible conformational change of the HA protein, resulting in
exposure of the fusion peptide, which inserts into the endoso-
mal target membrane of the host cell (18). After fusion of the
viral and endosomal membranes, the viral ribonucleoproteins
are released into the cytosol and transported into the nucleus,
where replication occurs (6). Crystallographic studies have
provided detailed insight into the processes of HA refolding
and extrusion of the fusion peptide (4). The latter is a sequence
of hydrophobic amino acids located at the N terminus of the
HA2 subunit, which is, in the prefusogenic conformation, se-
questered in a pocket of ionizable residues at the monomer
interface of the HA trimer (48). In order to exploit the HA
protein as an antiviral target, several small-molecule inhibitors
that block the acid-induced conformational change of HA have
been identified (2, 19, 21, 30, 49). For many of these, devel-
opment has been hindered by their subtype-dependent activi-
ties. On the other hand, these diverse fusion inhibitors repre-
sent excellent tools to identify the HA amino acid residues
involved in the fusion process and/or delineate the structural
differences among HA subtypes (36).
We report here the identification of a new class of influenza
A virus fusion inhibitors that have specific activity against the
H3 subtype, but not the H1, H5, and H7 subtypes. A detailed
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analysis of their structure-activity relationships and mecha-
nisms of action is described, with a focus on the interaction of
these compounds with the HA protein.
MATERIALS AND METHODS
Chemical synthesis of the compounds. Commercially available chemicals were
obtained from Merck, Aldrich, or Fluka. Melting points (M.p.) were determined
on a Buchi 530 capillary melting-point apparatus in open capillaries and were
uncorrected. Compound purity was measured by thin-layer chromatography
(TLC) on Silica gel 60 F254. Infrared (IR) spectra were recorded on a Perkin
Elmer 1600 FT infrared spectrophotometer in potassium bromide pellets ( in
cm1). 1H nuclear magnetic resonance (NMR) spectra were recorded on a
VarianUnity 500-MHz NMR spectrophotometer using tetramethylsilane as an
internal standard. Electron impact mass spectra (EIMS) were determined on a
VG Zab Spec (70-eV) spectrometer. Elementary analyses were performed on a
Carlo Erba 1106 and Elementar Micro Vario CHNS elemental analyzer at the
Scientific and Technical Research Council of Turkey. 2a, 2b, and 3b were re-
ported previously (45).
General synthesis of 2 (series II). A mixture of 0.005 mol 1 (45), 0.01 mol of
an appropriate ketone, a drop of concentrated H2SO4, and 10 ml of C2H5OH
(96%) was refluxed for 6 h. The crude product that precipitated on cooling was
filtered and recrystallized from a C2H5OH-H2O mixture.
6-Methyl-N-(4-phenylcyclohexylidene)imidazo[2,1-b][1,3]thiazole-5-carbo-
hydrazide (2c). M.p., 210 to 2°C; yield, 62.5%. IR, 3,280, 3,140 (NH), 1,625
(CO). 1H-NMR (CDCl3)  (ppm), 1.53–2.70 (9H, m, cyclohexane [cyclo-
hex.]), 2.47 (3H, s, imidazothiazole [imidazothia.]-C6-CH3), 6.70 (1H, d,
imidazothia.-C2-H), 7.00–7.14 (5H, m, phenyl), 8.05 (1H, d, imidazothia.-C3-
H), 8.32 (1H, s, CONH). EIMS (70 eV) m/z (%), 352 (M, 44), 165 (100).
Analysis: calculated for C19H20N4OS (352.453): C, 64.75; H, 5.72; N, 15.90.
Found: C, 64.97; H, 5.61; N, 15.66.
General synthesis of 3, 4, and 6 (series I and III). To a solution of 1 or 5 (0.005
mol) in dry benzene (30 ml) was added an appropriate ketone (0.01 mol), and the
mixture was refluxed for 1.5 h using a Dean-Stark trap. After the mixture was
cooled at room temperature, sulfanylacetic acid or 2-sulfanylpropanoic acid (0.15
mol) was added dropwise to the solution, and the resulting solution was refluxed
for 6 h. Excess benzene was evaporated in vacuo. The residue was triturated with
saturated NaHCO3 until CO2 evaluation ceased and was allowed to stand over-
night. The solid thus obtained was filtered, washed with H2O, and crystallized
from the C2H5OH-H2O mixture.
6-Methyl-N-(8-methyl-3-oxo-1-thia-4-azaspiro[4.5]dec-4-yl)imidazo[2,1-b][1,3]
thiazole-5-carboxamide (3a). M.p., 202 to 4°C; yield, 80.2%. IR, 3,153, 3,128
(NH), 1,698, 1,661 (CO). 1H-NMR ([D6]DMSO [dimethyl sulfoxide])  (ppm),
0.9 (3H, d, C8-CH3), 1.15–2.00 (9H, m, C6-10-H), 2.59 (3H, s, imidazothia.-C6-
CH3), 3.61 (2H, s, C2-H), 6.93 (1H, d, imidazothia.C2-H), 8.14 (1H, d, imid-
azothia.C3-H), 8.22 (1H, s, CONH). EIMS (70 eV) m/z (%), 364 (M, 52), 165
(100). Analysis, calculated for C16H20N4O2S2 (364.48): C, 52.72; H, 5.53; N,
15.37. Found: C, 53.01; H, 5.59; N, 15.82.
N-(3-oxo-8-phenyl-1-thia-4-azaspiro[4.5]dec-4-yl)-6-methylimidazo[2,1-
b][1,3]thiazole-5-carboxamide (3c). M.p., 238 to 9°C; yield, 86.9%. IR, 3,323,
3,110 (NH), 1,690, 1,658 (CO). 1H-NMR (CDCl3)  (ppm), 1.16–1.99 (8H,
m, -C6,7,9,10-H), 2.26 (1H, m, -C8-H), 3.47 (2H, s, -C2-H), 2.50 (3H, s, im-
idazothia.-C6-CH3), 6.99–7.13 (5H, m, phenyl), 6.78 (1H, d, imidazothia.-C2-
H), 7.87 (1H, s, CONH), 7.99 (1H, d, imidazothia.-C3-H). EIMS (70 eV) m/z
(%), 426 (M, 26), 165 (100). Analysis, calculated for C21H22N4O2S2
(426.55): C, 59.13; H, 5.20; N, 13.13. Found: C, 59.92; H, 4.55; N, 12.48.
6-Methyl-N-(2-methyl-3-oxo-1-thia-4-azaspiro[4.5]dec-4-yl)imidazo[2,1-
b][1,3]thiazole-5-carboxamide (4a). M.p., 220 to 1°C; yield, 21.9%. IR, 3,251,
3,131 (NH), 1,700, 1,658 (CO). 1H-NMR (CDCl3)  (ppm), 0.80–1.97 (10H, m,
C6-10-H), 1.57 (3H, d, C2-CH3), 2.56 (3H, s, imidazothia.-C6-CH3), 3.90 (1H, q,
-C2-H); 6.92 (1H, d, imidazothia.-C2-H), 8.13 (1H, d, imidazothia.-C3-H),
8.61(1H, s, CONH). EIMS (70 eV) m/z (%), 364 (M, 17), 165 (100). Analysis,
calculated for C16H20N4O2S2 (364.48): C, 52.72; H, 5.53; N, 15.37. Found: C,
53.00; H, 5.42; N, 15.19.
6-Methyl-N-(2,7-dimethyl-3-oxo-1-thia-4-azaspiro[4.5]dec-4-yl)imidazo[2,1-
b][1,3]thiazole-5-carboxamide (4b), M.p., 245 to 6°C; yield, 31.8%. IR, 3,250,
3,150 (NH), 1,700, 1,658 (CO). 1H-NMR ([D6]DMSO)  (ppm), 0.99 (3H, d,
C7-CH3), 1.43 (3H, d, C2-CH3), 1.50-1.90 (9H, m, C6-10-H), 2.57 (3H, s, imid-
azothia.-C6-CH3), 3.94 (1H, q, -C2-H), 7.36 (1H, d, imidazothia.-C2-H), 8.04 (1H,
d, imidazothia.-C3-H), 9.84 (1H, s, CONH). EIMS (70 eV) m/z (%), 378 (M,
30), 181 (100). Analysis, calculated for C17H22N4O2S2 (378.5): C, 53.94; H, 5.86;
N, 14.80. Found: C, 53.88; H, 5.68; N, 14.40.
6-Methyl-N-(2,8-dimethyl-3-oxo-1-thia-4-azaspiro[4.5]dec-4-yl)imidazo[2,1-
b][1,3]thiazole-5-carboxamide (4c). M.p., 165 to 7°C; yield, 37.0%. IR, 3,261,
3,131 (NH), 1,698, 1,656 (CO). 1H-NMR ([D6]DMSO)  (ppm): 0.81 (3H, d,
C8-CH3), 0.98-2.11 (9H, m, C6-10-H), 1.47 (3H, d, -C2-CH3), 2.57 (3H, s, imida-
zothia.-C6-CH3), 3.91 (1H, q, -C2-H), 7.35 (1H, d, imidazothia.-C2-H), 8.00 (1H,
d, imidazothia.-C3-H), 9.89 (1H, s, CONH). EIMS (70 eV) m/z (%): 378 (M,
42), 181 (100). Analysis, calculated for C17H22N4O2S2 (378.5): C, 53.94; H, 5.86;
N, 14.80. Found: C, 54.17; H, 5.55; N, 15.01.
6-Methyl-N -(8-ethyl-2-methyl-3-oxo-1-thia-4-azaspiro[4.5]dec-4-
yl)imidazo[2,1-b][1,3] thiazole-5-carboxamide (4d). M.p., 212 to 3°C; yield,
22.4%. IR, 3,246, 3,136 (NH), 1,701, 1,659 (CO). 1H-NMR ([D6]DMSO) 
(ppm), 0.79 (3H, t, C8-CH2-CH3), 1.00 to 1.26 (5H, m, C8-CH2CH3 and C6-10-H),
1.46 (3H, d, -C2-CH3), 1.59-2.03 (6H, m, C6-10-H), 2.56 (3H, s, imidazothia.-C6-
CH3), 3.94 (1H, q, C2-H), 7.38 (1H, d, imidazothia.-C2-H), 7.99 (1H, d, imida-
zothia.-C3-H), 9.87 (1H, s, CONH). EIMS (70 eV) m/z (%), 392 (M, 40), 181
(100). Analysis, calculated for C18H24N4O2S2 (392.53): C, 55.08; H, 6.16; N,
14.27. Found: C, 55.19; H, 5.94; N, 14.16.
6-Methyl-N-(2-methyl-3-oxo-8-phenyl-1-thia-4-azaspiro[4.5]dec-4-
yl)imidazo[2,1-b][1,3] thiazole-5-carboxamide (4e). M.p., 113 to 5°C; yield,
30.9%. IR, 3,283, 3,141 (NH); 1,702, 1,672 (CO). 1H-NMR ([D6]DMSO) 
(ppm), 1.61-2.21 (9H, m, C6-10-H), 1.49 (3H, d, -C2-CH3), 2.62 (3H, s, imida-
zothia.-C6-CH3), 3.89 (1H, q, C2-H), 7.18-7.29 (5H, m, phenyl), 7.40(1H, d,
imidazothia.-C2-H), 8.06 (1H, d, imidazothia.-C3-H), 9.96 (1H, s, CONH). EIMS
(70 eV) m/z (%), 441 (M,37), 252 (100). Analysis, calculated for C22H24N4O2S2
0.5 H2O (449.59): C, 58.77; H, 5.60; N, 12.46. Found: C, 58.85; H, 5.76; N, 12.46.
2-Hydroxy-N-(8-methyl-3-oxo-1-thia-4-azaspiro[4.5]dec-4-yl)benzamide (6a).
M.p., 247 to 9°C; yield, 88.5%. IR, 3,240 (OH/NH), 1,687, 1,659 (CO). 1H-
NMR ([D6]DMSO)  (ppm): 0.85 (3H, d, C8-CH3), 1.11-1.92 (9H, m, -C6-10-H),
3.62 (2H, s, -C2-H), 6.93-6.97 (2H, m, phenyl C3-H and C5-H), 7.45 (1H, t, phenyl
C4-H), 7.86 (1H, d, phenyl C6-H), 10.5 (1H, s, CONH), 11.5 (1H, s, OH).
Analysis, calculated for C16H20N2O3S. 0.5H2O (329.414): C, 58.33; H, 6.43; N,
8.50. Found: C, 58.73; H, 6.74; N, 8.40.
2-Hydroxy-N-(2,8-dimethyl-3-oxo-1-thia-4-azaspiro[4.5]dec-4-yl)benzamide (6b).
M.p., 159 to 61°C; yield, 97.8%. IR, 3,230 (OH/NH), 1,692, 1,655 (CO). 1H-NMR
([D6]DMSO)  (ppm): 0.84 (3H, d, C8-CH3), 1.08-1.99 (9H, m, -C6-10-H), 1.43 (3H,
d, -C2-CH3), 3.93 (1H, q, -C2-H); 6.93-6.98 (2H, m, phenyl C3-H and C5-H), 7.45
(1H, t, phenyl C4-H), 7.86 (1H, d, phenyl C6-H), 10.56 (1H, s, CONH), 11.5 (1H, s,
OH). Analysis, calculated for C17H22N2O3S (334.433): C, 61.05; H, 6.63; N, 8.38.
Found: C, 61.49; H, 6.78; N, 8.90.
Cells and virus strains. Madin-Darby canine kidney (MDCK) cells (a kind gift
from M. Matrosovich, Marburg, Germany) (22) were grown in Dulbecco’s mod-
ified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS)
(Integro), 1 mM sodium pyruvate, and 0.075% sodium bicarbonate. During virus
experiments, the MDCK cells were maintained in Ultra MDCK medium (Lonza,
Basel, Switzerland), supplemented with 0.0225% sodium bicarbonate, 2 mM
L-glutamine, and 2 g/ml tosylphenylalanylchloromethylketon (TPCK)-treated
trypsin (Sigma, St. Louis, MO).
The human influenza virus strains A/PR/8/34 (A/H1N1) and B/HK/5/72 were
purchased from the American Type Culture Collection (ATCC). The strains
A/X-31 (A/H3N2) (A/Aichi/2/68 [H3N2]  A/PR/8/34 [H1N1]) and A/HK/7/87
(A/H3N2) were obtained from J. Neyts (Katholieke Universiteit Leuven, Leu-
ven, Belgium), whereas the following strains were kindly provided by R. Fouchier
(Rotterdam, Netherlands): A/FM/1/47 (A/H1N1), A/HK/2/68, and A/Victoria/
3/75 (A/H3N2) and B/Lee/40. The A/H5N1 viruses A/Vietnam/1203/04 and
A/chicken/Vietnam/C58/04 were generated by reverse genetics with plasmids
kindly provided by R. Salomon and R. G. Webster (13, 32, 37). The A/H3N2
virus A/Aichi/2/68, used as a positive control in A/H5N1 plaque reduction assays,
was obtained from the ATCC. A/chicken/Pennsylvania/143586/02 (A/H7N2) was
kindly provided by R. G. Webster (14).
Virus stocks of these laboratory-adapted strains were prepared by passaging
them in 10-day-old embryonated chicken eggs. In addition, two clinical isolates
were included (A/Ned/378/05 [A/H1N1] and B/Ned/537/05; kind gifts from R.
Fouchier), which underwent one passage in embryonated hen eggs.
Antiviral assays. The following control compounds were included: ribavirin
(Virazole), obtained from ICN Pharmaceuticals; rimantadine (Sigma); and os-
eltamivir carboxylate (GS-4071) (a kind gift from T. Cihlar, Gilead Sciences,
Foster City, CA). The test compounds were evaluated for anti-influenza virus
activity by a multicycle cytopathic effect (CPE) reduction assay (28). MDCK cells
were seeded into 96-well plates at 7,500 cells per well 16 h prior to infection and
incubated at 35°C. Serial dilutions of the compounds were added to the cells,
together with the influenza virus (multiplicity of infection, 50 50% cell culture
infective doses [CCID50] per well, which corresponds to 0.0004 PFU per cell). At
3 days postinfection (p.i.), microscopy was performed to determine the antiviral
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activity, expressed as the compound concentration producing 50% inhibition of
virus-induced CPE (50% effective concentration [EC50]), as well as the cytotox-
icity of the compounds, expressed as the compound concentration causing min-
imal changes in cell morphology (MCC). The data were confirmed by the form-
azan-based 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium (MTS) cell viability assay (CellTiter 96 AQueous One
Solution Cell Proliferation Assay from Promega, Madison, WI), and the spec-
trophotometric data were used to calculate the EC50 and 50% cytotoxic concen-
tration (CC50).
In addition, the compound cytostatic activity was determined in uninfected
MDCK cells, which were incubated with serial dilutions of the compounds for
72 h and then subjected to cell counting with a Z1 Coulter Counter apparatus
(Beckman Coulter, Fullerton, CA). The data were expressed as the concentra-
tion causing 50% inhibition of cell proliferation (50% inhibitory concentration
[IC50]).
To determine the amount of virus released into the supernatant, cells were
incubated with virus and compounds as described above, and after 72 h, the
culture supernatant was collected from selected wells. After 2 l of the culture
medium was mixed with 1 l lysis enhancer and 10 l resuspension buffer (both
from the CellsDirect One-Step qRT-PCR kit; Invitrogen, Carlsbad, CA), the
samples were incubated at 75°C for 10 min and diluted 5-fold. Then, quantifi-
cation of viral-genome copies was performed with a one-step real-time reverse
transcription (RT)-PCR assay (CellsDirect One-Step qRT-PCR kit; Invitrogen).
The M1-FOR primer (5-CCTGGTATGTGCAACCTGTG-3) and M1-REV
primer (5-AGCCTGACTAGCAACCTCCA-3) were derived from the influ-
enza A virus M1 gene sequence and yielded an amplified fragment 193 bp long.
The M1-probe (6-FAM [6-carboxyfluorescein]-5-CTGACTCCCAGCATCGG
TCTCATAGGC-3-Black Hole Quencher [BHQ]; Eurogentec, Lie`ge, Belgium)
was chosen from within this sequence. Amplification was performed on an ABI
Prism 7000 apparatus (Applied Biosystems, Foster City, CA) and consisted of 15
min of cDNA synthesis at 50°C and a 2-min initial activation at 95°C, followed by
40 thermal cycles of 15 s at 95°C and 90 s at 60°C. In each experiment, a standard
curve (R2 	 0.99 within the range of 103 to 108 copies per reaction) was drawn
to convert the respective cycle threshold (CT) values into the number of viral-
genome copies. This standard consisted of a pCR2.1-TOPO plasmid construct in
which was cloned a 473-bp sequence of influenza virus A/PR/8/34 segment 7. All
samples were run in duplicate.
Plaque assay with influenza A/H5N1 and A/H7N2 viruses. Confluent mono-
layers of MDCK cells were grown in 6-well dishes overnight at 37°C. Compound
dilutions were added to the cells in the presence of A/H5N1 (A/Vietnam/1203/04
or A/Chicken/Vietnam/C58/04), A/H7N2 (A/Chicken/Pennsylvania/143586/02),
or A/H3N2 (A/Aichi/2/68) viruses diluted to 200 PFU/ml. The virus was allowed
to adsorb for 1 h at 37°C. The inoculum was removed, and the cells were washed
with phosphate-buffered saline (PBS) prior to being overlaid with minimal es-
sential medium (MEM) supplemented with 0.3% bovine serum albumin, 0.9%
Bacto agar, and 1 g/ml TPCK-treated trypsin. The infected cells were incubated
for a further 72 h at 37°C prior to removal of the overlay medium and staining
of the monolayer with crystal violet to visualize plaques. The EC50 was calculated
as the compound concentration yielding 50% reduction of the number of plaques
observed in untreated wells. Experiments with H5N1 and A/H7N2 viruses were
conducted in a U.S. Department of Agriculture-approved biosafety level 3
containment facility.
Time-of-addition experiment. MDCK cells were seeded into 24-well dishes at
125,000 cells per well. After 16 h of incubation at 35°C, influenza virus A/X-31
was added at a multiplicity of infection of 0.0004 PFU per cell, and the com-
pounds were added at 30 min, 0 h, 30 min, 1 h, 3 h, 5 h, or 8 h p.i. The reference
compounds were rimantadine, ribavirin, chloroquine (from Sigma), and bisin-
dolylmaleimide I (from Calbiochem). At 10 h p.i., the medium was discarded and
total cellular RNA extracts were prepared with the RNeasy Mini Kit (Qiagen,
Hilden, Germany). In order to quantify the viral RNA (vRNA), the samples were
analyzed by two-step real-time RT-PCR, using the M1-specific primers, probe,
and standard as described above. cDNA synthesis was performed on 0.5 g of
total RNA using Moloney murine leukemia virus (M-MLV) reverse transcriptase
(Invitrogen) and 500 nM M1-FOR primer. Then, real-time PCR was performed,
using the M1-FOR and M1-REV primers, the M1 probe (see above), and qPCR
MasterMix (Eurogentec). The thermal profile consisted of a 10-min initial acti-
vation at 95°C, followed by 40 thermal cycles of 15 s at 95°C, 30 s at 60°C, and
40 s at 72°C. In each experiment, a standard curve (R2 	 0.99 within the range
of 103 to 108 copies per reaction) was drawn to convert the respective CT values
into the number of viral-genome copies. All samples were analyzed in duplicate.
Hemolysis inhibition assay. The procedure to determine the inhibitory effects
of the compounds on virus-induced hemolysis at low pH was slightly adapted
from Luo et al. (20). After preincubation of 100 l allantoic influenza virus stock
with 100 l compound (serially diluted in PBS) at 37°C for 1 h, an equal volume
of chicken red blood cells (RBC) (2% in PBS) was added. The samples were
incubated at 37°C for 10 min, and then the RBC (with adsorbed virus) were
centrifuged (300  g; 4°C; 8 min). The RBC pellets were resuspended in 450 l
PBS buffer containing the corresponding concentrations of the compounds, and
the pH was lowered to 5.0 by addition of a predetermined amount of 1 N acetic
acid. After incubation at 37°C for 25 min, the reaction was neutralized with
NaOH, and intact chicken RBC were removed by centrifugation (400  g; 8 min;
4°C). Then, 300 l of the supernatant was transferred to a 96-well plate, and the
optical density was measured at 540 nm with a Spectramax Plus apparatus
(Molecular Devices, Union City, CA). Background values were derived from
mock-infected samples that underwent identical treatment. The data were ex-
pressed as the EC50 relative to the value observed in the absence of compound.
Trypsin susceptibility assay. To determine the inhibitory effect of 4c on the
acid-induced conformational change of HA, which renders HA susceptible to
tryptic digestion, influenza virus A/X-31 (allantoic stock diluted 1:10 in PBS) was
incubated in the presence of various compound concentrations at 37°C for 15
min. The pH was lowered to 5.0 by addition of a predetermined amount of 1 M
sodium acetate buffer (pH 4.8). After 10 min of incubation at 37°C, the mixture
was neutralized to pH 7.2 by the addition of 0.5 M Tris-HCl buffer (pH 9.0).
Then, samples were incubated in the presence of 10 mg per ml trypsin (Sigma)
at 37°C for 1 h. The reaction was terminated by incubation (20 min at 37°C) with
5 mg per ml soybean trypsin inhibitor (Sigma). Subsequently, the samples were
mixed with protein extraction buffer (20 mM Tris-HCl, pH 7.4, 0.137 M NaCl, 2
mM Na2EDTA, 1% Triton X-100, 10% glycerol, 1 mM phenylmethylsulfonyl
fluoride, 0.01 mg leupeptin per ml). The lysates were clarified (10 min at
23,000  g) and analyzed by Bradford assay. After being mixed with loading dye
containing 50 mM dithiothreitol and boiled for 3 min, aliquots containing 20 g
of total protein were loaded on 12% Tris-glycine SDS-polyacrylamide gels. Then,
electrophoresis and electroblotting onto Hybond-P membranes (GE Healthcare)
were performed, and the membranes were blocked overnight in 5% fat-free
powdered milk in PBS. The blots were subjected to two washes with PBS
containing 0.1% Tween 20 (PBS-T), 1 h of incubation with 5 g per ml of
primary antibody (anti-HA1 mouse monoclonal antibody clone InA246;
HyTest), three washes in PBS-T, 45 min of incubation with secondary antibody
(horseradish peroxidase-linked goat anti-mouse immunoglobulin polyclonal an-
tibody; Dako), and six final washes in PBS-T. Protein bands were visualized with
a ECL Plus Western blotting detection system (GE Healthcare) and exposed to
X-ray film.
Selection and characterization of resistant mutants. The influenza virus strain
A/X-31 was passaged on MDCK cells in the presence of 20, 20, and 150 M 4c
for the first, second, and third passages, respectively. The final supernatant was
harvested and plaque purified on 0.8% agar, and individual clones were incu-
bated for 72 h on MDCK cells in the presence of 100 M 4c. The cellular
fractions were subjected to RNA extraction (RNeasy Mini Kit; Qiagen), followed
by reverse transcription with M-MLV reverse transcriptase (Invitrogen) and a
primer derived from the 3 terminus of hemagglutinin, amplification of the
cDNA by high-fidelity PCR (Expand High Fidelity PCR System; Roche, Mann-
heim, Germany), and cycle sequencing. The supernatant fractions were used as
virus stocks in an antiviral CPE reduction assay as described above. In parallel,
these stocks were inoculated in embryonated eggs, and the allantoic fluids were
subjected to virus titration by cell culture and hemagglutination assay and virion
quantification by two step real-time RT-PCR (as described above). Finally, these
allantoic stocks were used to perform a hemolysis inhibition assay with the test
compounds and to determine the pH of erythrocyte hemolysis for the mutant
viruses.
Polykaryon assay for fusion of cells expressing wild-type or mutant HA. The
coding sequence for the A/X-31 HA was obtained by RNA extraction of A/X-
31-infected MDCK cells, followed by reverse transcription and high- fidelity
PCR, and was then cloned into the pcDNA3.1 D/V5-His-TOPO vector (Invitro-
gen). After generation of the mutant plasmids by site-directed mutagenesis (with
the QuikChange Site-Directed Mutagenesis Kit; Stratagene), the wild-type and
mutant HA sequences were amplified by high-fidelity PCR using primers ex-
tended with EcoRV and NotI sites to allow subcloning into the pCAGEN
expression vector (kindly provided by C. Cepko [Boston, MA] via Addgene
[plasmid no. 11160]) (23). The final plasmids were checked by cycle sequencing
of the HA fragments.
To perform the polykaryon assay, HeLa cells were seeded into 12-well plates
at 300,000 cells per well. One day later, transfection with the wild-type or mutant
pCAGEN-HA plasmid (0.73 g DNA per well) was performed using Fugene 6
reagent (Roche) and serum-free medium. After 3 h, the transfection medium
was replaced by medium containing 2% FCS. Two days later, the cells were
washed with DMEM, and the HA was cleaved by incubation with TPCK-treated
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trypsin (2.5 g per 0.5 ml DMEM) for 15 min at 37°C. After two rinses with PBS
containing Ca2 and Mg2 (PBS-CM), the cells were preincubated with 0.5 ml
test compound (diluted in PBS-CM) for 15 min at 37°C. Then, the compound
was removed, and the cells were incubated with 0.5 ml acidic buffer (PBS-CM
adapted to pH 5.0 with 0.1 M citric acid) containing the corresponding concen-
tration of test compound. After exactly 15 min of incubation at 37°C, the cells
were rinsed with PBS-CM, and 1 ml medium containing 10% FCS was added,
followed by 3 h of incubation at 37°C. Finally, the cells were fixed with 96%
ethanol, stained with Giemsa (Sigma), and examined by microscopy at 200
magnification. To score syncytium formation, the number of polykaryons (con-
taining five or more nuclei) was counted in four randomly selected microscopic
fields. To determine the fusion pH of wild-type and mutant HAs, the experi-
ments were performed in the absence of compound, but the pH of the acidic
buffer was varied (range, 4.9 to 6.0).
Molecular modeling. (i) X-ray structure. In all docking experiments, the re-
cently published X-ray structure of the H3 hemagglutinin trimeric protein in
complex with tert-butyl hydroquinone (TBHQ) was used (Protein Data Bank
[PDB] entry 3EYM [36]). The HA1 chains were denoted the A, C, and E chains,
whereas B, D, and F are the HA2 chains. For the numbering of amino acid
residues, a suffix 1 or 2 indicates their location in the HA1 or HA2 subunit,
respectively.
(ii) Preparation of the compounds and the HA protein for docking. The
N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide compounds were drawn using
Macromodel 5.0 (25). The Cambridge Structural Database (CSD) entry
OFEGIQ was used as a template for the conformation of the aliphatic six-
member ring (1). The molecular geometry was fed into Gamess for geometry
optimization using the AM1 force field (38). Polar hydrogen atoms, as well as
Gasteiger charges, were added to the protein and compound structures using
autodock tools.
(iii) Docking of 4c in the HA structure. For the different HA residues associ-
ated with 4c resistance, the calculated solvent accessibility was at least 100 Å2 for
A432 and E572, whereas R2201, A962, and D1122 had values of 20 Å2 or less (33).
Docking experiments with 4c (after removal of TBHQ) were therefore restricted
to A432 and E572, using Autodock 4 software (26) and a grid size of 50 by 50 by
50 points and 0.375-Å resolution. When all protein residues were kept rigid, no
specific interactions between 4c and E57(F) were observed. Superposition of
chains B, D, and F (using the Dali server [http://www.ebi.ac.uk/Tools/dalilite
/index.html]) showed that the orientation of the side chain of E57 differed among
the three monomers, implying that this E57 residue is flexible and adopts dif-
ferent rotameric states. From these, we selected rotameric state (
1  49,84,

2  74.84, 
3  160.79), which orients the glutamic acid side chain in the
direction of the cavity, for 4c docking. After docking, the top 50 of docked ligand
conformations were examined, and the highest-score conformation was selected
based on the following criteria: specific hydrogen bonding with the E57(F) side
chain and hydrophobic interactions with the R and R2 methyl groups of 4c.
Interactions (H bonds and hydrophobic) were calculated using Ligplot and




ide derivatives against human influenza A/H3N2 virus. The
anti-influenza virus activities of a series of structurally related
N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide compounds
(Fig. 1) were determined by measuring their inhibitory effects
FIG. 1. Strategy for chemical synthesis of the compounds.
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on virus replication in MDCK cells, using two strains of the
influenza A/H3N2 virus subtype. The antiviral data obtained by
microscopic evaluation of the virus-induced CPE were con-
firmed by the MTS cell viability assay and expressed as the
EC50. The cytotoxicities of the compounds were expressed as
the MCC (the compound concentration causing minimal alter-
ations in cell morphology as estimated by microscopy) or the
CC50 (the compound concentration causing 50% reduction in
cell viability based on the MTS assay). Analysis of the struc-
ture-activity relationships revealed that the strongest antiviral
activity was observed for the compounds 4c and 4d, in which
the R substituent at position 8 of the spiro ring (Fig. 1) is a
methyl and ethyl substituent, respectively. Both compounds
had an average EC50 of 3.7 M (Table 1). 4c showed minimal
cytotoxicity at the highest concentration tested (100 M),
yielding a selectivity index (SI) (defined as the ratio of MCC to
EC50) of 27. 4d had a lower SI of 14. The importance of the
substituent at position 8 was evident from the data showing
that 4b, which has a methyl group at position 7 (R1) (Fig. 1)
instead of 8, was 11-fold less active than 4c, while the com-
pounds having no substituent (4a) or an 8-phenyl group (4e)
were devoid of antiviral activity. Likewise, the methyl substit-
uent in the spiro ring (R2) (Fig. 1) was shown to play an
important role, since the analogues of 4c and 4d lacking this
function (3a and 3b, respectively) were inactive. Similarly, re-
moval of the spiro ring was found to be deleterious (com-
pounds 2a, 2b, and 2c). A few compounds were synthesized
with variations in the aromatic system. Substitution of the
imidazo[2,1-b]thiazole ring (4c) by an o-hydroxyphenyl ring
(6b) resulted in a minimal increase in antiviral activity; how-
ever, 6b was also more cytotoxic. The analogue lacking the
methyl in the spiro ring (6a) was inactive.
In contrast to the promising activities of 4c, 4d, and 6b against
influenza A/H3N2 virus, these compounds were completely inac-
tive against A/H1N1 and B viruses (Table 2). In addition, 4c was
shown to be inactive in a plaque assay with influenza A/H5N1 or
A/H7N2 virus (highest concentration tested, 100 M). The
A/H3N2 (A/Aichi/2/68) virus, included as a control, displayed an
EC50 of 7.5 M, which is similar to the value obtained in the CPE
reduction assay. This defined subtype dependency was consistent
upon evaluation against a broad panel of human influenza virus
strains (Table 2). Overall, 4c, 4d, and 6b had average EC50s for
A/H3N2 of 9.6 M, 3.7 M, and 4.4 M, respectively. A cell-
counting assay was used to precisely estimate their cytostatic ac-
tivities (expressed as the IC50), and from this their selectivity
indexes (i.e., ratio of IC50 to EC50) values were calculated as 10,
13, and 9 for 4c, 4d, and 6b, respectively. The strong activities of
4c and 4d were also evident from a virus yield experiment, since
both compounds (at a concentration of 20 M) produced a 3- to
4-log-unit reduction in the number of virus particles released in
the supernatant of infected MDCK cells at 72 h p.i. (data not
shown).
4c acts within 30 min postinfection. A one-cycle time-of-
addition experiment was performed in which the antiviral com-
pounds were added at different time points p.i. (range, 30
min to 8 h). As reference compounds, we included the M2
proton channel blocker rimantadine; the weak base chloro-
quine (which acts by increasing the endosomal pH); the pro-
TABLE 1. Activity in influenza A/H3N2 virus-infected MDCK cellsa
Compoundb R R1 R2
Antiviral EC50c (M) Cytotoxicityd
A/X-31 A/HK/7/87
MCC (M) CC50 (M) IC50 (M)
CPE MTS CPE MTS
Series I
3a Me H H 	100 	100 	100 	100 	100 ND ND
3b Et H H 	100 	100 	100 	100 	100 ND ND
3c Phe H H 	100 	100 	100 	100 100 ND ND
4a H H Me 100 100 	100 	100 	100 ND ND
4b H Me Me 32  17 44 42  4 40 	100 ND ND
4c Me H Me 3.3  1.3 3.2  2.0 5.0  2.3 3.2  2.3 100 	100 93
4d Et H Me 2.4  2.1 4.0  3.8 4.2  3.3 4.3  3.0 50 	50 48
4e Phe H Me 	100 	100 	100 	100 100 ND ND
Series II
2a Me 	100 	100 	100 	100 100 ND ND
2b Et 	100 	100 	100 	100 	100 ND ND
2c Phe 	100 	100 	100 	100 	100 ND ND
Series III
6a Me H 	300 	300 	300 	300 60 	300 ND
6b Me Me 2.6  2.3 5.9  4.3 2.8  1.8 1.4  0.6 	50 	50 38
Oseltamivir carboxylate 0.0042  0.0035 0.020  0.040 1.7  1.9 0.63  0.23 	100 	100 80
Ribavirin 9.9  3.3 11  4 7.4  2.1 7.2  3.8 61  30 	100 18
a The data shown are the means  standard deviations of 2 to 7 independent tests. ND, not done. MDCK cells, Madin-Darby canine kidney cells; Et, ethyl; Me,
methyl; Phe, phenyl.
b Figure 1 shows the basic structures of the N-(1-thia-4-azaspiro4.5decan-4-yl)carboxamide compounds, series I, II, and III.
c Antiviral activity is expressed as the EC50, defined as the compound concentration producing 50% inhibition of virus replication, as estimated by microscopic scoring
of the CPE or by measuring cell viability in the formazan-based MTS assay.
d Cytotoxicity is expressed as the MCC, the compound concentration producing minimal changes in cell morphology, as estimated by microscopy; the CC50, estimated
by the MTS cell viability assay; or the IC50, determined by cell counting.
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tein kinase inhibitor bisindolylmaleimide I (which has been
shown to inhibit the nuclear import of the viral ribonucleopro-
tein complex) (34); and ribavirin, an inhibitor of viral-RNA
synthesis. In the absence of compounds, the increase in vRNA
copies between time point zero (input virus) and 10 h p.i. was
170-fold (Fig. 2). No vRNA synthesis was detected when 4c
was added at 30 min or 0 min p.i. In contrast, its inhibitory
effect was considerably reduced when the compound was
added at 30 min p.i. or later. The same time dependency was
observed for rimantadine and chloroquine, while the time-of-
addition curve was slightly shifted for bisindolylmaleimide I.
Ongoing vRNA synthesis between 1 and 8 h p.i. was reflected
in the gradual curve obtained with ribavirin treatment.
The N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide de-
rivatives inhibit virus-mediated hemolysis. As 4c was found
not to influence the attachment of influenza virus to erythro-
cytes in a hemagglutination assay (data not shown), an inhib-
itory effect of 4c on the interaction between HA and cellular
receptors was excluded. Next, a hemolysis inhibition assay was
performed to determine whether 4c and its derivatives inhibit
hemagglutinin-mediated interactions with target membranes.
For several strains of A/H3N2 influenza virus, the hit com-
pounds inhibited the acid-induced hemolysis with EC50s of 3
M (4c), 3 M (4d), and 1.6 M (6b) (Table 3). Since 4c
and 4d showed no inhibitory effect on hemolysis by influenza
A/H1N1 and B viruses, the subtype-dependent activity, as ob-
served in the CPE reduction experiment, was confirmed. Also,
6a and 3a showed much weaker inhibition of influenza
A/H3N2 virus-induced hemolysis. For 4b and 4a, no inhibition
was noted at a concentration of 100 M. 4c proved to be highly
inhibitory when the compound was present during both the
10-min virus-erythrocyte adsorption stage and the subsequent
TABLE 2. Antiviral activities in influenza A/H1N1, A/H3N2, and B virus-infected MDCK cellsa
Strain
Antiviral EC50b (M)
4c 4d 6b Ribavirin Oseltamivir carboxylate
CPE MTS CPE MTS CPE MTS CPE MTS CPE MTS
A/H1N1
A/FM/1/47 	50 	50 	50 	50 	50 38  10 12  3 13  1 4.0  2.9 4.0  2.2
A/Ned/378/05 	50 	50 	50 	50 	50 21  14 8.4  2.2 6.1  2.9 0.19  0.06 0.20
A/PR/8/34 	50 	50 	50 	50 	50 	50 10  0 12  5 12  7 6.3
A/H3N2
A/X-31 3.3  1.3 3.2  2.0 2.4  2.1 4.0  3.8 2.6  2.3 5.9  4.3 9.9  3.3 11  4 0.0042  0.0035 0.020  0.040
A/HK/2/68 7.4  2.8 4.6  3.0 3.4  1.3 1.8  1.4 5.4  3.2 2.7  1.1 11  1 9.1  1.3 1.2  1.0 0.20
A/Victoria/3/75 23  17 27  20 6.0  1.5 3.7  3.2 7.1  3.9 7.2  5.2 8.7  3.7 7.7  4.1 0.20 0.20
A/HK/7/87 5.0  2.3 3.2  2.3 4.2  3.3 4.3  3.0 2.8  1.8 1.4  0.6 7.4  2.1 7.2  3.8 1.7  1.9 0.63  0.23











B/HK/5/72 	50 	50 	50 	50 	50 	50 5.8  2.9 11  9 1.7  0.9 2.2  0.9
B/Lee/40 	50 	50 	50 	50 	50 	50 15  6 15  9 	20 	20
B/Ned/537/05 	50 	50 	50 	50 	50 	50 6.6  3.1 7.9  0.3 2.2  2.3 1.7  1.7
a The data shown are the means  standard deviations of 2 to 7 independent tests.
b Antiviral activity is expressed as the EC50, defined as the compound concentration producing 50% inhibition of virus replication, as estimated by microscopic scoring
of the CPE or by measuring cell viability in the formazan-based MTS assay.
c Data obtained by plaque reduction assay.
FIG. 2. Inhibitory effect of 4c on vRNA synthesis as a function of
the time of compound addition. MDCK cells were infected with
A/X-31 influenza virus, and compounds were added at 30 min, 0 h,
30 min, 1 h, 3 h, 5 h, or 8 h p.i. At 10 h p.i., the cells were subjected to
RNA extraction for subsequent analysis by real-time RT-PCR. The
vRNA synthesis is presented as the fold increase in vRNA copies at
10 h p.i. relative to the number of added virus particles. The data
shown are the means  standard deviations (SD) (the numbers of
experiments are in parentheses).
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acid-induced hemolysis event. In contrast, no effect was ob-
served when 4c was washed away after the adsorption stage,
indicating that the binding of 4c to HA is reversible.
4c inhibits HA-mediated membrane fusion by prevention of
the HA conformational change at low pH. HeLa cells express-
ing the A/X-31 HA were exposed to pH 5.0 in the absence or
presence of 4c, and the subsequent fusion of cell membranes
and syncytium formation were evaluated by microscopy. As
can be seen in Fig. 3, 4c produced dose-dependent inhibition of
polykaryon formation, since no syncytia were formed when 4c was
added at5 M 15 min prior to, as well as during, the acid stage.
In order to investigate whether 4c exerts its fusion-inhibiting
effect by directly preventing the conformational change of HA
at acidic pH, a tryptic digestion assay was used, which is based
on the exposure of trypsin cleavage sites when HA changes
from its prefusogenic to its fusogenic conformation (41). As
shown in Fig. 4, the HA1 subunit of the A/X-31 virus was
clearly protected against trypsin cleavage when the virus was
incubated in the presence of 4c at 10 or 100 M.
Genotypic and phenotypic characterization of 4c-resistant
mutants. 4c-resistant (4cr) mutants were selected during three
passages of the A/X-31 strain in MDCK cells at 4c concentra-
tions up to 100 M. After clonal purification, three clones
(designated 4cr-A, 4cr-B, and 4cr-C) were isolated. Three con-
trol clones were obtained from a parallel condition in which no
compound was added. As the biological data for the control





A/PR/8/34 A/FM/1/47 A/X-31 A/HK/7/87 A/HK/2/68 A/Vict/3/75
3a ND ND 29 ND ND ND ND
4a ND ND 	100 ND ND ND ND
4b ND ND 	100 ND ND ND ND
4c 	100 	100 3.0  0.9 30  29 4.2  0.9 2.6 	100
4d 	100 	100 3.2  1.1 15 6.7  4.2 2.5  0.0 	100
6a ND ND 12  1 ND ND ND ND
6b ND ND 1.6 ND ND ND ND
a The inhibitory effect, determined by hemolysis inhibition assay, was expressed as the EC50, i.e., the compound concentration producing 50% inhibition of
virus-induced hemolysis relative to the value at pH 4.9. Means ( standard deviations) of 1 to 4 independent experiments are shown. ND, not done.
FIG. 3. 4c inhibits low-pH-induced polykaryon formation. HeLa cells expressing wild-type A/X-31 HA were treated with trypsin to cleave HA0,
washed, and incubated in the presence of various concentrations of 4c. Then, the pH was lowered to 5.0, and the cells were incubated for 15 min
at 37°C in the presence of 4c. Following syncytium formation for 3 h at 37°C in medium, the cells were fixed, stained with Giemsa, and examined
by microscopy (original magnification, 200). Representative fields are shown.
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clones were identical, they were pooled. In CPE reduction
experiments, replication of all three 4cr clones was not inhib-
ited by 4c, 4d, and 6b at compound concentrations of 100 M,
whereas the EC50 of the control was in the same range ob-
served previously (Table 4). The antiviral sensitivities of the 4cr
clones to the control compounds ribavirin and oseltamivir car-
boxylate were unchanged, since the EC50s were similar to those
obtained for the control. The 4cr clones were, however, resis-
tant to the M2 blocker rimantadine. The 4c-resistant pheno-
type of the 4cr clones was confirmed by the hemolysis inhibi-
tion assay: none of the three clones was inhibited in its
hemolytic activity at 4c and 4d concentrations of 100 M.
After isolation of the 4c-resistant and control clones, the HA
gene was sequenced. Clones 4cr-A and 4cr-B were triple mu-
tants, both of which contained the substitutions R2201S and
E572K. A third substitution (Ala to Thr) was found at either of
two positions: 4cr-A showed an A432T substitution and 4c
r-B
contained an A962T substitution. The 4c
r-C clone was geno-
typically distinct, since it contained a single D1122N substitu-
tion. In addition, several amino acid changes compared to the
published X-31 sequence were noted, but these were identical
in the 4c-resistant and control clones.
To compare the binding efficiencies and replication fitness of
the selected clones, the viruses were inoculated into hen eggs,
and the resulting allantoic fluids were subjected to virus titra-
tion by cell culture, hemagglutination assay, and real-time RT-
PCR. The results (Table 5) indicate that the fitness of the
resistant mutants was not compromised, since the allantoic
fluids contained comparable numbers of virions (assessed by
RT-PCR) that were equally effective in binding to erythrocytes
or replicating in cell culture.
To determine the fusion pHs of the 4c-resistant and control
clones, hemolysis assays were performed in which the pH dur-
ing the acid-induced fusion stage was varied (pH range, 4.6 to
6.0). The fusion pHs, defined as the pH at which 50% hemo-
lysis occurred, were 5.4, 5.3, and 5.5 for 4cr-A, 4cr-B, and 4cr-C,
respectively, compared to 5.1 for the control (Fig. 5). Thus, the
4c-resistant viruses, whether they contained one (4cr-C) or
three (4cr-A and 4cr-B) substitutions in the HA protein, dis-
played an elevated fusion pH. The increase was more pro-
nounced for the 4cr-A and 4cr-C clones than for the 4cr-B
clone. This increase in the fusion pH also explains the resis-
tance of the 4cr clones to rimantadine. It is known that high
concentrations of adamantane compounds have a pH-increas-
ing effect in the endosomes, which can be counteracted by
resistance mutations in the HA, leading to increased fusion pH
(8). The relatively high antiviral EC50 of rimantadine for the
wild-type virus suggests that the virus is insensitive to the
specific M2 proton channel-blocking effect of the adaman-
tanes.
Membrane fusion characteristics of mutant HA proteins
containing 4c-associated substitutions. To determine the phe-
notypic consequences of the 4c-associated HA protein muta-
tions, wild-type and single-mutant HA genes were expressed in
HeLa cells to perform the polykaryon fusion assay at low pH.
The EC50s for inhibition of syncytium formation by 4c were
0.90, 1.8, 2.1, 7.9, and 23 M for the wild-type and R2201S-,
A432T-, E572K-, and D1122N-substituted HAs, respectively
(Table 6). 4c produced no inhibition of membrane fusion in
cells containing the A962T-substituted HA protein (highest
concentration tested, 50 M). Thus, the E572K, A962T, and
D1122N substitutions resulted in resistance to the fusion-in-
hibiting effect of 4c. By varying the pH of the acidic buffer
(range, 4.9 to 6.0) to which the HA-expressing cells were ex-
posed, the fusion pH was determined. Strong increases in the
fusion pH were observed for the R2201S, A962T, and D1122N
mutants, whereas the A432T- and E572K-substituted HAs dis-
played the same fusion pH as wild-type HA protein.
Locations of the HA residues associated with 4c resistance
and molecular modeling for 4c binding. Figure 6A shows the
locations of the five amino acid residues associated with viral
TABLE 4. Antiviral sensitivities of 4c-resistant mutants
Clonea
EC50 (M)b
CPE assayc Hemolysis assayd
4c 4d 6b Rimantadine Ribavirin Oseltamivircarboxylate 4c 4d
4cr-A 	100 	100 	100 	500 12  0 0.14  0.15 	100 	100
4cr-B 	100 	100 	100 	500 12  1 0.046  0.020 	100 	100
4cr-C 	100 	100 	100 	500 13  0 0.37  0.36 	100 	100
Control 2.7  1.1 1.8  1.0 1.5  0.9 58  2 12  1 0.10  0.14 3.9  1.1 4.0  0.8
a 4cr-A, 4cr-B, and 4cr-C, clones selected under 4c pressure; control, pooled data from three clones selected in the absence of compound.
b The data shown are the means ( standard deviations) of four independent tests.
c Antiviral activity in Madin-Darby canine kidney cells was expressed as the EC50, as estimated by microscopic scoring of the CPE.
d The inhibitory effect, determined by hemolysis inhibition assay, was expressed as the EC50 at low pH.
FIG. 4. Effect of 4c on the conformational change of HA, as dem-
onstrated by trypsin digestion. A/X-31 virus was incubated at 37°C for
15 min in the presence of various concentrations of 4c, and the pH was
lowered to 5.0. After neutralization, the mixtures were treated with
trypsin. The lysates were subjected to Western blot analysis under
reducing conditions and using an anti-HA1 antibody. The low-pH-
induced conformational change of the HA resulted in the disappear-
ance of the HA1 band.
4284 VANDERLINDEN ET AL. J. VIROL.






resistance to 4c within the available crystal structure of HA
X-31 in complex with the H3-specific fusion inhibitor TBHQ.
Each of the three HA regions suggested to be critically in-
volved in the conformational change at low pH (43) appeared
to be involved in 4c resistance. R2201 is located at an inter-
subunit interface in a coil region within the globular head of
the HA trimer and is involved in hydrogen bonds and hydro-
phobic interactions. Residues A432 and D1122 are located in
the same cavity, with A432 located at the entrance and D1122
at the bottom of this cavity. A432 shows local hydrophobic
interactions, and D1122 forms hydrophobic interactions and
hydrogen bonds with the nearby fusion peptide (8). The other
two residues are situated at the entrance (E572) and bottom
(A962) of the TBHQ binding pocket. E572 forms intrasubunit
hydrogen bonds and hydrophobic interactions and is involved
in TBHQ binding (36). With A962, local hydrophobic interac-
tions were observed.
Computer-aided docking (in the HA X-31 crystal structure
after removal of TBHQ) was performed to predict the possible
binding pocket for 4c in the HA trimer in the vicinity of any of
the observed resistance mutations. R2201, A962, and D1122
were found to be solvent inaccessible. 4c was observed to fit
within a cavity close to E572, and several hydrophobic interac-
tions between the surrounding residues and 4c were observed
in which the R and R2 methyl groups of 4c were also involved
(Fig. 6B). The nitrogen atom of its carboxamide bridge forms
hydrogen bonds with the side chain carboxyl of E572 and the
main chain carbonyl of R542. Similar interactions within this
E572 cavity were obtained with the 8-ethyl analogue 4d and the
o-hydroxyphenyl analogue 6b (data not shown). Replacement
of this E572 residue by lysine results in loss of the hydrogen
bond between the glutamic acid carboxyl function and 4c. Al-
ternatively, a change in charge could modify the local structure
of the cavity, influencing the binding of 4c. Besides these hy-
drogen bonds, multiple hydrophobic interactions were ob-
served between 4c and its binding pocket, namely, with resi-
dues I291, P2931, K3071, R542, V552, K582, T592, Y942, E972,
L982, L992, and A1012 (Fig. 6B). Interestingly, the position of
the aliphatic cyclic part of 4c within this hydrophobic cavity was
clearly similar to that of TBHQ, which also forms a hydrogen
bond with E572 (as well as with L982) and hydrophobic inter-
actions with L291, R542, L552, E972, L982, L992, and A1012
(36). However, the imidazo[2,1-b]thiazole part of 4c allows the
formation of several additional hydrophobic interactions.
DISCUSSION
Fusion between the viral and endosomal membranes is an
essential event during influenza virus entry into the host cell.
FIG. 5. pH dependence of hemolysis for wild-type and 4c-resistant
mutants. A hemolysis assay was performed in which the pH of the
acidic buffer was varied between 4.6 and 6.0. The y axis shows the
degree of hemolysis, expressed as the optical density at 450 nm
(OD540) minus the blank value obtained from a mock-infected condi-
tion. 4cr-A, 4cr-B, and 4cr-C, clones selected under 4c pressure; con-
trol, pooled data from three clones selected in the absence of com-
pound. The values in parentheses are the pHs at which 50% hemolysis
occurred relative to the value at pH 4.9.
TABLE 5. Receptor binding and replication fitness of 4c-resistant virus mutantsa







4cr-A R2201S, A432T, E572K 5.0E7 128 1.1E7 2.5 0.23
4cr-B R2201S, E572K, A962T 3.3E7 176 5.5E6 5.3 0.17
4cr-C D1122N 9.3E7 256 3.2E7 2.8 0.34
Control 9.3E7 341 3.6E7 3.7 0.39
a The individual clones were expanded in eggs, and the allantoic fluids were subjected to virus titration by cell culture (expressed as the CCID50) and hemagglutination
assay (expressed as the number of hemagglutinating units HAU). Virion quantification was done by real-time RT-PCR. The data shown are the mean of two
independent tests.
b 4cr-A, 4cr-B, and 4cr-C, clones selected under 4c pressure; control, pooled data from three clones selected in the absence of compound.
TABLE 6. Analysis of 4c-associated HA substitutions in a




R2201S 5.5  0.1
c 1.8  0.7
A432T 5.2  0.1 2.1  1.5
E572K 5.2  0.1 7.9  0.6
c
A962T 5.5  0.0
c 	50c
D1122N 5.6  0.1
c 23c
Wild type 5.2  0.1 0.90  0.40
a The fusion pH was defined as the pH at which the number of syncytia was
50% of the number observed at pH 4.9.
b The EC50 represents the compound concentration at which the number of
syncytia was 50% of the number observed in the absence of compound.
c P  0.05 (two-sided Student’s t test) for a statistically significant difference
versus the value of the wild type.
Data shown are the mean ( standard deviations) of three independent tests.
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After endocytosis of the virion, the influenza virus HA protein
undergoes an irreversible acid-induced structural rearrangement
in which the highly hydrophobic fusion peptide, located at the
amino terminus of HA2, is exposed and projected toward the
endosomal membrane (42). Since this conformational change is
crucial for the fusogenic activity of HA and viral entry, this event
is an attractive target for the development of antiviral agents.
In the present work, we described a new series of N-(1-thia-4-
azaspiro[4.5]decan-4-yl)carboxamide inhibitors that show marked
antiviral activity against influenza A/H3N2 viruses in a CPE re-
duction assay. For the lead compound, 4c, the average EC50 for
influenza A/H3 viruses was 9.6 M and the IC50 was 93 M,
yielding a selectivity index of 10. Time-of-addition experiments
with 4c revealed that the compound acts at an early step in virus
replication, i.e., within 30 min p.i. The subtype-dependent activity
of the N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide deriva-
tives, and the time-of-addition curve for 4c, pointed to the influ-
enza virus HA protein as the possible target. Whereas 4c did not
influence the attachment of influenza virus to erythrocytes in a
hemagglutination assay, the compound showed strong inhibition
of virus-induced hemolysis. Moreover, the structure-activity rela-
tionship obtained in hemolysis inhibition studies agreed with the
results of the CPE reduction assay. Hence, the available data are
consistent with the mechanism of action for 4c and its congeners
being the inhibition of HA protein-mediated membrane fusion.
Several classes of small molecules that inhibit influenza virus
fusion have been reported previously (2, 5, 30, 49). While most of
these compounds inhibit the acid-induced conformational
change, diiodofluorescein was shown to act in an irreversible
manner by premature triggering of this HA conformational
change (12). For 4c, the first mechanism of action was suggested
by our observation that no inhibition of hemolysis occurred when
the compound was washed away after the virus-erythrocyte ad-
sorption stage and prior to acid-induced fusion. Definite proof of
this mode of action was provided by the tryptic digestion assay, in
which 4c prevented the acid-induced conversion of HA to its
trypsin-sensitive conformation.
Most reported fusion inhibitors have subtype-dependent ac-
tivities, and for the majority, the activity against the influenza
A/H1 and A/H2 strains is superior to that against A/H3 strains
(21, 30, 49). One exception is the antiviral drug arbidol, which
displays antiviral activity against a broader range of subtypes
and was recently reported to act as a fusion inhibitor (19). The
small benzoquinones and hydroquinones, with TBHQ being
the most potent, were, until now, the only known class of
A/H3-specific fusion inhibitors (2). The class of N-(1-thia-4-
azaspiro[4.5]decan-4-yl)carboxamide inhibitors we describe in
this report shows specific activity against influenza A/H3 vi-
ruses. This is surprising, since the backbone structure of our
inhibitors is related to that of some A/H1- and A/H2-specific
inhibitors, consisting of an aromatic system linked to a non-
aromatic cyclic system via an amide bridge (20, 30). To obtain
FIG. 6. Positions of 4c-associated HA mutations and the predicted binding pocket of 4c in the HA protein. The modeling was based on the published
crystal structure of the X-31 HA in complex with TBHQ (36). (A) Ribbon diagram showing the locations of the amino acid residues (R2201, A432, E572,
A962, and D1122) involved in 4c resistance. The HA1 chains are colored in sky blue (A chain), royal blue (C chain), and slate blue (E chain); HA2 chains
are in pink (B chain), flesh (D chain), and purple (F chain); and the fusion peptide is indicated in green. The frame indicates the position of the binding
pocket of 4c. (B) Chimera model of the interactions of 4c in the binding pocket around glutamic acid-57. The numbering of the amino acid residues
includes the polypeptide chain (HA1 chains, A, not visible; C, white; and E, cyan; HA2 chains, B, not visible; D, orange; and F, khaki). Predicted hydrogen
bonds with the main chain carbonyl of R542 and the side chain carboxyl of E572 are shown as dashed lines, with the distance indicated in angstroms.
Residues I291, R542, V552, K582, and T592, indicated on the protein structure, and residues P2931, K3071, Y942, E972, L982, L992, and A1012 (not visible)
are involved in hydrophobic interactions with 4c (shown in green; note that the cyclohexane part is not displayed). The predicted position of the
N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide moiety of 4c is similar to that of TBHQ (shown in purple). 4c-specific hydrophobic interactions were
observed between its imidazo[2,1-b]thiazole part and residues P2931, K3071, K582, and T592.
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a more detailed insight into this subtype dependency, we also
evaluated the compounds against influenza A/H5 and A/H7
viruses, an issue which has not been investigated for the other
reported fusion inhibitors. The inclusion of these emerging
subtypes not only has implications for antiviral drug develop-
ment, but also may aid us to understand the mode of action of
4c and its derivatives. Whereas the inactivity of 4c against
A/H5 virus was not totally surprising, the insensitivity of the
A/H7 virus was quite unexpected. Russell et al. performed a
phylogenetic analysis of all 16 HAs based on the available
crystal structures of representative HAs, including some re-
gions involved in fusion (35). The H1 and H5 HAs are closely
related and belong to the same group 1, while the H3 and H7
HAs are more distantly related and represent the two clades
within group 2. The different activities of 4c against H3 and H7
viruses may thus reflect the fact that the region in H3 HA
involved in binding of 4c differs from the corresponding region
in H7 HA. We addressed this issue by characterizing 4c-resis-
tant virus mutants and investigating the roles of the individual
substitutions in a polykaryon assay in cells expressing mutant
HA proteins. Experience with the other fusion inhibitors has
shown that the HA mutations selected by these compounds
may be explained by reduced binding of the inhibitor and/or
decreased stability of the HA trimeric protein, and hence an
increase in the fusion pH. Among the 4c-associated mutations,
the A962T and D1122N substitutions were shown to reduce
HA trimer stability, rendering HA resistant to the fusion-in-
hibiting effect of 4c. On the other hand, the observation that
E572K-substituted HA displayed an unchanged fusion pH yet
9-fold-greater resistance to 4c is suggestive of a role of this
residue in 4c binding, which was also proposed by our com-
puter-aided docking. Interestingly, residue E572 is directly in-
volved in binding of another H3-specific fusion inhibitor,
TBHQ, as demonstrated by cocrystallization studies with the
X-31 HA (36). We noticed a clear similarity between the po-
sition of TBHQ and that predicted for the N-(1-thia-4-
azaspiro[4.5]decan-4-yl)carboxamide part of 4c. However, the
aromatic imidazo[2,1-b]thiazole ring of 4c allows the formation
of several additional hydrophobic interactions within this cav-
ity. Although our modeling pointed to residue A432 as an
alternative potential binding site for 4c (data not shown), we
consider this to be less likely, since substitution of this residue
did not result in significant resistance to 4c. In addition, A432
was changed in only one of the 4c-resistant viruses, whereas the
E572K mutation was present in both triple-mutant clones. The
finding that 4c and TBHQ have a stabilizing effect on HA upon
binding to E572 and the nearby cavity is in agreement with the
critical role played by the adjacent lysine-58, since the K582I
mutation leads to stabilization of the HA proteins of the H3
and H5 subtypes (31, 32, 44). The single D1122N mutation
observed in the third 4c-resistant virus clone has previously
been identified in virus mutants with increased pH values for
conformational changes and membrane fusion, including
TBHQ-resistant H3 mutants (8, 12, 32). Thus, although 4c and
TBHQ have very different chemical structures, there is a clear
parallel in their interaction modes with the H3 HA.
The R2201S substitution is intriguing, since it is located in
the globular-head domain of the HA trimer, in which muta-
tions associated with resistance to fusion inhibitors (whether
H1 or H3 specific) are not commonly observed. Residue 220 is
located at the intersubunit interface (7), at some distance from
the receptor binding site. The R2201S substitution does not
impact the erythrocyte binding properties of the HA, as was
evident from our hemagglutination experiments with the mu-
tant viruses. The same substitution was recently identified dur-
ing mouse adaptation of an H3 virus, a process that is known
to select for viruses with increased fusion pH (15). Likewise,
we demonstrated that the 4c-associated mutations, including
R2201S, have no impact on viral fitness, since the virus mutants
showed equal erythrocyte binding and replication efficiencies
and all mutations were stable when the mutant viruses were
expanded in eggs. On the other hand, an HA protein alignment
showed that the 5 residues that were mutated in 4c-resistant
viruses were conserved among the five H3N2 strains included
in our study. Likewise, all 13 residues involved in hydrogen
bonding and/or hydrophobic interactions of 4c within its pre-
dicted HA binding pocket were identical in these five H3N2
viruses, except for K3071 and V552, at which positions strain
A/HK/7/87 contains R3071 and L552. Although this subtle dif-
ference could account for the lower sensitivity of this virus to
4c in the hemolysis test, its relevance is unclear, since all five
H3N2 viruses displayed comparable sensitivities to 4c in the
replication assay in MDCK cells.
Fusion inhibitors such as 4c are excellent tools to further
delineate the structural changes during the HA-unfolding pro-
cess. Our results show that the A962 and R2201 residues play
important roles in HA stabilization, which was not previously
demonstrated. The data we gained on the binding of 4c to the
pocket around glutamic acid-57 confirm the relevance of this
HA cavity in the structure-based design of fusion inhibitors.
Computer-aided design of new derivatives of 4c could poten-
tially lead to compounds with improved antiviral effect and less
confined subtype dependency.
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